Oncotarget

Clinical Research Papers:

Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response

Yingqiang Zhang _, Wenzhe Fan, Kangshun Zhu, Ligong Lu, Sirui Fu, Jinhua Huang, Yu Wang, Jianyong Yang, Yonghui Huang, Wang Yao and Jiaping Li

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:24550-24559. https://doi.org/10.18632/oncotarget.4076

Metrics: PDF 1536 views  |   HTML 1624 views  |   ?  


Abstract

Yingqiang Zhang1, Wenzhe Fan1, Kangshun Zhu2, Ligong Lu3, Sirui Fu3, Jinhua Huang4, Yu Wang1, Jianyong Yang5, Yonghui Huang5, Wang Yao1, Jiaping Li1

1Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

2Department of Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

3Department of Interventional Oncology, Guangdong General Hospital, Guangzhou, China

4Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center & State Key Laboratory of Oncology in Southern China, Guangzhou, China

5Department of Interventional Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Correspondence to:

Jiaping Li, e-mail: [email protected]

Keywords: hepatocellular carcinoma, transarterial chemoembolization, radiofrequency ablation, complete response, sorafenib

Received: March 04, 2015     Accepted: May 21, 2015     Published: June 03, 2015

ABSTRACT

Aims: To assess the efficacy of continued administration of sorafenib for patients with unresectable hepatocellular carcinoma (HCC) treated with local regional therapy (LRT) after a complete response (CR), also, the adverse events of sorafenib after discontinuation of administration were observed.

Methods: Between April 2008 and May 2012, 956 consecutive patients with unresectable HCC treated with LRT (transarterial chemoembolization, radiofrequency ablation) combined with sorafenib were retrospectively investigated. Of these, 157 patients with a CR were enrolled: 102 of them continued to receive sorafenib (test group) and the other 55 stopped receiving sorafenib (control group).

Results: The median recurrence-free survival (RFS), post-complete response overall survival (pOS) and overall survival (OS) in the test and control groups were 11 months (95% CI: 6.1, 15.9), 25 months (95% CI: 20.7, 29.3) and 33 months (95% CI: 29.2, 36.8) and 12 months (95% CI: 10.4, 13.6), 28 months (95% CI 24.2, 31.8) and 34 months (95% CI: 30.8, 37.2) respectively. The differences in RFS, pOS and OS between the groups were not significant (P = 0.768, 0.797 and 0.730, respectively). The adverse events related to sorafenib resolved after discontinuation of administration and the quality of life (QoL) scores improved.

Conclusions: Patients with unresectable HCC who achieved a CR did not benefit from continued sorafenib in terms of RFS, pOS or OS. The adverse events of sorafenib were reversible, and discontinuation of sorafenib may improve the QoL of patients who have achieved a CR.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4076